Abstract 883P
Background
Mandibular bone resection is indicated in case of bone invasion or close contact with the tumor. The microvascular bone free flap (MBFP) is the reconstruction of choice. Despite a higher risk of complications, it allows oral rehabilitation. However, many patients do not benefit from it. We sought to assess the rate of non-rehabilitated patients and the reasons why.
Methods
This multicenter study was carried out in 6 centers in France. Patients were included if treated between January 2017 and January 2022 for head and neck carcinoma with MBFP. Patients who had relapsed or died were excluded. Included patients completed a telephone questionnaire.
Results
Of the 175 identified patients, 104 patients were finally included. Median follow-up since initial surgery was 26 months (min 18-max 60 months). MBFP consisted of a fibular free flap in 83% of cases, a scapular free flap in 16% of cases and an iliac crest free flap in 1% of cases. 61 patients (59%) had no oral rehabilitation. 17% of these patients had never been informed of the possibilities of oral rehabilitation, and 20% of these patients had never met any oral rehabilitation specialist. 22% of patients had an unsuccessful attempt at oral rehabilitation (removable prosthesis or implant-supported prosthesis). Of the 43 rehabilitated patients, 81% had a removable prosthesis and 19% an implant-supported prosthesis. Neither the number of osteotomies, nor the complexity of the reconstruction, nor the pre- or post-operative history of radiotherapy, nor the use of cutting guides were statistically associated with oral rehabilitation in this series. Only the presence of an oral rehabilitation specialist in the center had a significant influence on the rehabilitation rate (p=0.004), irrespective of the surgeon's specialty.
Conclusions
This is the first multicenter study to evaluate the rate of oral rehabilitation after free bone flap reconstruction for malignancy. Only 41% of patients benefited from rehabilitation. Regardless of the complexity of the reconstruction, the only factor influencing oral rehabilitation was the presence of an oral rehabilitation specialist in the center.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
782P - Predicting survival in malignant struma ovarii (MSO): A machine learning approach
Presenter: Sakhr Alshwayyat
Session: Poster session 02
Resources:
Abstract
783P - ESCAT gene actionability detection in early-stage ovarian: A descriptive analysis of an Italian referral center
Presenter: Floriana Camarda
Session: Poster session 02
784P - Prognostic nomograms for gestational and non-gestational choriocarcinoma: A population-based study
Presenter: Mustafa Alshwayyat
Session: Poster session 02
785P - Online prognostic calculator for gestational trophoblastic neoplasia (GTN): A tool for personalized treatment planning
Presenter: Zena Haddadin
Session: Poster session 02
786P - Exploring risk factors for recurrence in stage I uterine leiomyosarcomas: Is there a subgroup with a favorable prognosis?
Presenter: Alejandro Gallego
Session: Poster session 02
787P - First-in-human, phase I study of CBP-1008, a first-in-class bi-specific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors
Presenter: Ning Li
Session: Poster session 02
788P - Pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)
Presenter: Natalie Ngoi
Session: Poster session 02
789P - Translational study and preliminary clinical trial of WX390 monotherapy in cancers with concurrence of PIK3CA and ARID1A mutations
Presenter: Jiajia Li
Session: Poster session 02
790P - The landscape of human epidermal growth factor receptor 2 (HER2) expression in gynecologic tumors (GTs)
Presenter: Carmen Garcia Duran
Session: Poster session 02
791P - Activity of ERK1/2 inhibitor ASTX029 in patients with gynecological malignancies harboring genomic alterations in the MAPK pathway
Presenter: Geoffrey Shapiro
Session: Poster session 02